<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To estimate the prevalence of and the cardiovascular risk associated with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> using the new definition proposed by the World Health Organization RESEARCH DESIGN AND METHODS: A total of 4,483 subjects aged 35-70 years participating in a large family study of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in Finland and Sweden (the Botnia study) were included in the analysis of cardiovascular risk associated with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In subjects who had type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 1,697), impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (IFG)/<z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) (n = 798) or <z:hpo ids='HP_0000855'>insulin-resistance</z:hpo> with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT) (n = 1,988), the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> was defined as presence of at least two of the following risk factors: <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, or <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Cardiovascular mortality was assessed in 3,606 subjects with a median follow-up of 6.9 years </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In women and men, respectively, the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> was seen in 10 and 15% of subjects with NGT, 42 and 64% of those with IFG/IGT, and 78 and 84% of those with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The risk for <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> was increased threefold in subjects with the syndrome (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Cardiovascular mortality was markedly increased in subjects with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (12.0 vs. 2.2%, P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Of the individual components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, <z:mp ids='MP_0002959'>microalbuminuria</z:mp> conferred the strongest risk of cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> (RR 2.80; P = 0.002) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The WHO definition of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> identifies subjects with increased <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality and offers a tool for comparison of results from diferent studies </plain></SENT>
</text></document>